Skip to content
Open in App
Novartis AG DRC SA logo

Novartis AG DRC SA

web2

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical...

Symbol · N1VS34
Company profile

About

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Explore by sector

Explore this sector

Presentation

Watch Novartis AG DRC SA

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Completed acquisition of Avidity Biosciences

KEY STEP

Novartis completed its acquisition of Avidity Biosciences on February 27, 2026. Avidity became an indirect wholly owned subsidiary of Novartis, adding its muscle directed Antibody Oligonucleotide Conjugate platform and three late stage neuromuscular programs to the Novartis pipeline.

Roadmap reference

FDA approves Pluvicto for PSMA positive metastatic hormone sensitive prostate cancer

KEY STEP

On July 31, 2026, the FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for adults with PSMA positive metastatic hormone sensitive prostate cancer. Novartis said the expanded indication makes Pluvicto available across PSMA positive metastatic prostate cancer and nearly doubles the eligible patient population.

Roadmap reference
People

Company team

GC

Giovanni Caforio

Independent Chairman of the Board

Company leadership profile.

SE

Simon E. Moroney

Independent Vice Chairman of the Board

Company leadership profile.

DL

Daniel Luzius Vasella

Honorary Chairman

Company leadership profile.

TB

Ton Buechner

Independent Non-Executive Director

Company leadership profile.

ED

Elizabeth Doherty

Independent Non-Executive Director

Company leadership profile.

PB

Patrice Bula

Lead Independent Director

Company leadership profile.

NC

Nancy C. Andrews

Independent Non-Executive Director

Company leadership profile.

FA

François Adrianus van Houten

Independent Non-Executive Director

Company leadership profile.

BP

Bridgette P. Heller

Independent Non-Executive Director

Company leadership profile.

AM

Ana María de Pro Gonzalo

Independent Non-Executive Director

Company leadership profile.

JD

John D. Young

Non-Executive Independent Director

Company leadership profile.

EM

Elizabeth McNally

Independent Director

Company leadership profile.

RC

Robert Charles Swanton

Independent Director

Company leadership profile.

Expert coverage

2 experts evaluated Novartis AG DRC SA.

Orbitrum research

Experts evaluating Novartis AG DRC SA

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment